Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
39.56
+0.47 (+1.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,165,019
Open
39.34
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
39.09
Today's Range
39.24 - 39.62
52wk Range
29.20 - 42.43
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
October 18, 2024
From
Genentech
Via
Business Wire
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
Performance
YTD
+8.83%
+8.83%
1 Month
+0.25%
+0.25%
3 Month
+0.51%
+0.51%
6 Month
+27.98%
+27.98%
1 Year
+18.59%
+18.59%
More News
Read More
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
October 15, 2024
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
Via
Investor's Business Daily
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
October 14, 2024
From
Genentech
Via
Business Wire
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
Via
Benzinga
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
October 10, 2024
From
Genentech
Via
Business Wire
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
October 10, 2024
Via
Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
October 08, 2024
Via
Benzinga
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Via
Benzinga
Exposures
Product Safety
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
October 06, 2024
Via
Benzinga
Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million
October 05, 2024
Via
Talk Markets
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Via
Investor's Business Daily
3 Top Stocks That Could Still Rocket Higher in 2024
October 04, 2024
Via
The Motley Fool
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
Via
Benzinga
Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
September 26, 2024
From
Genentech
Via
Business Wire
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
September 21, 2024
Via
Investor's Business Daily
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
September 19, 2024
Via
Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
September 19, 2024
From
Genentech
Via
Business Wire
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Via
The Motley Fool
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
September 16, 2024
Via
Benzinga
Exposures
Product Safety
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
September 13, 2024
From
Genentech
Via
Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.